Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | TERT | O14746 | 2/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.59 |
| ▸ | DTYMK | P23919 | 4/20 | 0.58 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
| ▸ | TYMS | P04818 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350192 | 1.00 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29671382 | 1.00 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29775052 | 1.00 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL34463741 | 1.00 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL15672415 | 0.97 | F2 (0.65) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29534179 | 0.96 | F2 (0.63) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29533485 | 0.96 | F2 (0.63) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29408579 | 0.95 | F2 (0.62) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL23009655 | 0.95 | DTYMK (0.67) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL30103510 | 0.95 | DTYMK (0.67) | F2POLBTERTP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | claimed |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | claimed |
| CN-117545509-A | Oral delivery of oligonucleotides | 四纬生物制药股份有限公司 | 2024-02-09 | — | — | CN | claimed |
| US-20240026305-A1 | RECOMBINANT ONCOLYTIC VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | DEVACELL, INC. | 2024-01-25 | — | — | US | claimed |
| US-20230364222-A1 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | DEVACELL, INC. | 2023-11-16 | — | — | US | claimed |
| CN-116942832-A | Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus | 归属疗法有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230272420-A1 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | DEVACELL, INC. | 2023-08-31 | — | — | US | claimed |
| EP-4161545-A2 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | Devacell, Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | claimed |
| CN-110471098-B | Radon radiation dose detection method based on carbon quantum dot fluorescence biosensor | 广东医科大学 | 2022-10-25 | — | — | CN | claimed |
| CN-114994027-A | Colorimetric method for detecting sulfur dioxide | 广东轻工职业技术学院 | 2022-09-02 | — | — | CN | claimed |
| WO-2022109503-A1 | RECOMBINANT ONCOLYTIC VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | DEVACELL, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| WO-2022076756-A1 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | DEVACELL, INC. (US) | 2022-04-14 | — | — | WO | claimed |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| CN-114222729-A | Amino acid transport inhibitors and uses thereof | 范德比尔特大学 | 2022-03-22 | — | — | CN | disclosed |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-17 | — | — | US | disclosed |
| US-20220062278-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | HMGB3, HCCS, ACACA | F2 4469/4885POLB 2779/4885TERT 4017/4885 |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | F2 4588/4885POLB 808/4885TERT 1858/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885POLB 1103/4885TERT 3199/4885 |
| US-20220062278-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | AR, KLK3, FSHR | F2 4865/4885POLB 2341/4885TERT 2082/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | F2 4584/4885POLB 1624/4885TERT 2597/4885 |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885POLB 1103/4885TERT 3199/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | F2 1607/4885POLB 4417/4885TERT 3142/4885 |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | GLS, GLUL, GLS2 | F2 2636/4885POLB 1521/4885TERT 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.